Current Report Filing (8-k)
September 20 2022 - 07:04AM
Edgar (US Regulatory)
0001589150 false 0001589150 2022-09-19
2022-09-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): September
19, 2022
REGEN BIOPHARMA, INC.
(Exact name of small business issuer as specified in its
charter)
Nevada |
45-5192997 |
(State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
Commission File No.333-191725
4700 Spring Street, St
304, La
Mesa, California 91942
(Address of Principal Executive Offices)
(619) 722
5505
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
|
None |
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act.
Item 8.01 Other
Events.
On September 19, 2022 Regen
Biopharma, Inc. (the “Company”) issued a press release titled
“Regen BioPharma, Inc. Files Patent on Paradigm Shifting
RNA/DNA-Based Approach to Cancer Immunotherapy” the text of which
is attached to this Current Report on Form 8-K as Exhibit 99.1. The
purpose of this Current Report on Form 8-K is to further clarify
the information contained within the aforementioned press
release.
The invention which is the
subject of the provisional patent application which is the subject
of the press release attached to this Current Report as Exhibit
99.1 is intended at expanding the use of the Company’s patented
technology to inhibit a T cell checkpoint called NR2F6. The Company
has multiple patented and patent-pending approaches to treating
cancer directly or via immunotherapy. Immunotherapy drugs are ones
which manipulate the body’s own immune system to clear it of
cancer. By releasing the natural brake in T cells, the Company
expects that its drugs will allow a patient’s immune cells to be
highly activated. The Company is pursuing several such approaches
within this very competitive field of cancer treatment. Therefore,
the Company has a patent portfolio built around cellular therapies,
small molecules, aptamers and RNA vaccines.
Item 9.01 Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
REGEN
BIOPHARMA, INC. |
|
|
Dated: September 20, 2022
|
By: /s/ David Koos |
Regen Biopharma (PK) (USOTC:RGBP)
Historical Stock Chart
From Jan 2023 to Feb 2023
Regen Biopharma (PK) (USOTC:RGBP)
Historical Stock Chart
From Feb 2022 to Feb 2023